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Abstract
Hemophilia is an inherited recessive sex-linked bleed-
ing disorder. An insufficiency of coagulation factor VIII 
produces hemophilia A, and lack of factor IX causes 
hemophilia B. Prevention and management of the dis-
ease require intravenous infusion of the deficient factor. 
Worldwide, hemophilia affects approximately 600,000 
people, 20% of whom develop antibodies against the 
deficient coagulation factor. Hemophilic patients with 
inhibitors present with multiarticular joint degenera-
tion (hemophilic arthropathy) secondary to recurrent 
hemarthroses. The availability of activated prothrombin 
complex concentrates and activated recombinant factor 
VII allows hemophilic patients with high inhibitor titers to 
undergo elective orthopedic surgery with a high expec-
tation of success, and thorough individual case analysis 
by a multidisciplinary team allows surgeons to obtain 
satisfactory results. However, the rate of potential com-
plications must not be underestimated.
Development of an inhibitor against factor VIII (FVIII) or factor IX (FIX) is the most common and most serious complication of replacement therapy in patients with hemophilia A or B. The 
rate of inhibitor development is approximately 20%. 
Two approaches to treating patients with inhibi-
tors have been proposed. Immune tolerance induction 
using high-dose FVIII or FIX daily or twice daily for 
a period ranging from a few months to several years 
may completely eliminate the inhibitor and allow the 
patient to be treated efficiently with FVIII or FIX 
again.1,2 However, immune tolerance induction fails in 
approximately 20% of cases and is not recommended 
for all patients because of the high probability of failure 
or adverse events. Furthermore, this procedure is costly. 
The other proposed approach to treating patients with 
inhibitors is to manage bleeding episodes with activated 
prothrombin complex concentrates (APCCs), such as 
“factor eight inhibitor bypassing activity” (FEIBA),3-5 
or with activated recombinant factor VII (rFVIIa; 
NovoSeven, Novo Nordisk A/S, Bagsværd, Denmark).6-9 
Should APCCs or rFVIIa fail to manage life- or limb-
threatening bleeds, or fail as first-line management for 
major bleeds, surgeons can consider high-dose human10 
or porcine11 FVIII or human FIX, which may be effi-
cacious when the inhibitor is low or is lowered using 
plasmapheresis12 or protein A immunoadsorption.13 
However, the anamnestic rise of the inhibitor renders 
management with FVIII or FIX ineffective within a few 
days, making the patient resistant to rescue with FVIII 
or FIX for months or even years. 
For acute hemarthrosis in patients with inhibitors, 
hematologic management must be maintained until 
bleeding goes into full remission and the patients have 
recovered as much of  their preoperative range of 
motion and muscular strength as possible. Such a regi-
men, which can take up to 3 months, has come to be 
known as enhanced on-demand treatment. In this con-
nection, ultrasonography is a reliable, economical, and 
easy-to-use method for diagnosing hemarthrosis and 
following up on its evolution.14 
OrthOpedic Surgery in hemOphilic patientS 
With inhibitOrS
Between the second and fourth decades of life, many 
hemophilic patients develop arthropathy. At this stage, 
possible treatments include alignment osteotomy, 
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Figure 1. Radiosynovectomy (rhenium-186) of ankle in patient 
with inhibitor and chronic hemophilic synovitis.
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arthroscopic joint débridement, arthrodesis, and total 
joint arthroplasty.15 For the hip, cemented or press-fit 
uncemented components can be used; for the knee, a 
posterior-stabilized cemented design is advised. In hemo-
philia, muscular problems must not be underestimated, 
given the risk for developing compartment syndrome, 
which requires surgical decompression, and pseudotu-
mors, which require surgical removal or percutaneous 
management.
The surgical techniques that can be performed in 
hemophilic patients include joint aspiration, radiosyno-
vectomy (RS) (Figure 1), arthroscopic synovectomy, 
arthroscopic joint débridement, alignment osteotomy, 
tendon lengthening, ankle arthrodesis (Figure 2), ankle 
arthroplasty, total knee arthroplasty (TKA) (Figure 3), 
placement of external fixators for progressive exten-
sion of joints with flexion contracture, neurolysis of 
entrapped nerves, arthrotomy for septic arthritis, drain-
age of infected hematomas, removal or percutaneous 
management of pseudotumors, fasciotomy for decom-
pression of compartment syndrome, and various types 
of osteosynthesis for bone fractures.16,17 
In some cases, a double or triple surgical proce-
dure can be performed in a single session to solve the 
functional problem in a comprehensive way. This tactic 
undoubtedly increases anesthesia and bleeding risks, 
but it also saves coagulation factor and avoids addi-
tional surgical sessions.18 Surgery must be performed 
with intravenous antibiotic prophylaxis for 24 to 48 
hours. For patients with hemophilia, treatment must 
be individualized. Surgery must be performed in col-
laboration with the hematologist, who is responsible for 
maintaining adequate hemostasis during all phases of 
treatment (bolus or continuous infusion). The hemato-
logic treatments most commonly used for patients with 
inhibitors are rFVIIa and APCCs.19 Several publica-
tions have indicated that, with appropriate hemostasis, 
a high degree of safety can be maintained during surgi-
cal treatment of patients with inhibitors.20-23 According 
to these publications, most authors use rFVIIa for 
major surgery, though others obtain satisfactory results 
with APCCs.
In an international study involving 8 hospitals, 108 
patients with inhibitors were treated.21 RS was per-
formed in 88 of these patients (47 with APCCs, 31 with 
rFVIIa, 10 with other methods) and major surgery in 
the other 20 (17 with rFVIIa, 3 with APCCs).
In 2010, we described 35 orthopedic surgeries in hemo-
philic patients with inhibitors.24 Both rFVIIa and APCCs 
appeared to be effective, though bibliographic data 
showed that hematologists have a predilection for using 
Figure 2. Patient with inhibitor underwent right ankle arthrodesis with locked retrograde intramedullary nail. (A) Preoperative clinical 
view shows severe arthropathy. (B) Radiographs confirm intense hemophilic arthropathy of ankles (more severe in right ankle). (C) 
Postoperative anteroposterior view shows satisfactory result. 
A B C
Figure 3. Patient with inhibitor underwent left total knee arthro-
plasty. Note normal bleeding after tourniquet release and 
implantation of prosthetic components.
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rFVIIa in major surgery. With respect to minor orthope-
dic surgery (RS), we injected 27 joints (27 patients) with 
either yttrium (90Y), for knees, or rhenium (186Rh), for 
ankles and elbows. In 20 of these 27 cases, APCCs were 
used; in the other 7, rFVIIa was used. With respect to 
major orthopedic surgery, we performed 8 orthopedic 
procedures (6 patients): 3 TKAs, 1 total hip arthroplasty, 
1 fixation of bone fracture, 1 ankle arthrodesis, 1 removal 
of hardware from ankle fusion, and 1 knee arthrodesis. 
Of these 8 procedures, 6 were performed with rFVIIa and 
2 with APCCs. Of the 35 orthopedic procedures total, 
22 were performed with APCCs and 13 with rFVIIa.24 
There was 1 complication, a pseudoaneurysm of a 
geniculate artery after a TKA. The pseudoaneurysm was 
eventually occluded by arterial embolization (vascular 
stent), and the outcome was excellent.
Regarding appropriate hematologic perioperative 
treatment, it has been reported that rFVIIa infusion 
at 50 µg/kg/h provides adequate hemostatic control for 
patients with inhibitors during major orthopedic sur-
gery.25 Habermann and colleagues26 stated that a safe 
and economical therapy for guaranteeing hemostasis in 
major elective orthopedic surgery consists of immuno-
adsorbent therapy to reduce inhibitors before surgery, 
perioperative substitution of FVIII, and switching to 
rFVIIa when inhibitors are increased. On the other 
hand, monotherapy with rFVIIa allows immediate 
surgical intervention, without a long hospital stay 
before surgery and the need for laboratory monitoring 
of inhibitor titers and FVIII levels. Bolus infusion and 
continuous infusion of rFVIIa appear to be comparable 
in their hemostatic efficacy in surgical management of 
hemophilic patients with inhibitors.27 Giangrande and 
colleagues28 described a new rFVIIa protocol for elec-
tive orthopedic surgery. In this protocol, which is based 
on a review of published data as well as the personal 
experience of a group of expert physicians, an initial 
bolus dose of rFVIIa, in the range of 120 to 180 µg/kg-1,
is used to cover surgery. In all cases, there was good 
control of hemostasis during surgery, and the final out-
come was rated excellent or extremely satisfactory by 
the reporting clinicians. Although the initial cost of the 
product to cover surgery, such as arthroplasty, is high, 
this cost may be offset in subsequent years by savings 
resulting from fewer bleeding episodes in the affected 
joint. Takedani and colleagues29 reported that the com-
bination of bolus and continuous infusion of rFVIIa is 
safe and effective, and its administration is more conve-
nient than simple bolus infusion therapy is in achieving 
hemostasis during the perioperative period. According 
to Caviglia and colleagues,30 bypassing agents can be 
used to achieve good control of hemostasis in hemo-
philic patients with inhibitors who undergo minor and 
major elective orthopedic surgery. Our recommended 
hematologic treatment is outlined in Tables I and II.22
minOr OrthOpedic Surgery
When continuous prophylaxis is not feasible because of 
expense or lack of venous access, we must aggressively 
manage major hemarthroses and perform arthrocente-
sis to prevent progression to synovitis, recurrent joint 
bleeds, and, ultimately, end-stage osteoarthritis (hemo-
philic arthropathy).5 When chronic hemophilic synovitis 
is being managed, RS should always be performed first 
(Figure 1). Should RS fail 3 times (6-month intervals), 
arthroscopic synovectomy is indicated. RS consists 
of the intra-articular injection of radioactive mate-
rial (yttrium-90, rhenium-186, phosphorus-32) capable 
of reducing the degree of synovial hypertrophy, and 
therefore the number and frequency of hemarthroses. 
Table I. Recommended Dosage of Activated Prothrombin Complex Concentrate 
for Orthopedic Surgery22
Dosagea
Surgery Preoperative Days 1–5 Days 6–14
Minor 50-75 U/kg 50-75 U/kg every 12-24 h, 1 or 2 doses —
Major 75-100 U/kg 75-100 U/kg every 8-12 h 75-100 U/kg every 12 h
aMaximum, 250 U/kg/d.
Table II. Recommended Dosage of Recombinant Activated Factor VII for Orthopedic Surgery22
Dosage
Surgery Infusion Preoperative Days 1–5 Days 6–14
Minor/major Bolus 90-120 µg/kg  
(ped. 120-150 µg/kg)
90-120 µg/kg every 2 h, up to 4 doses,  
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RS is commonly used in the management of recurrent 
intra-articular bleeds and secondary chronic synovitis 
in hemophilic patients. The administered agent induces 
fibrosis in the inflamed synovium and reduces the 
bleeding tendency. Whichever agent is used, care must 
be taken to avoid the extra-articular complications (eg, 
radiation burn, inflammatory reaction) that can result 
from extravasation or needle-track contamination. In 
hemophilia, the joints that are most often affected are 
the elbows, knees, ankles, and, to a lesser extent, the 
shoulders and hips.
Elbows, knees, and ankles may be injected on an out-
patient basis and under local anesthesia. However, it is 
advisable to inject shoulders and hips under radiograph-
ic guidance to ensure accurate placement. Very young 
children may require either sedation or general anesthe-
sia. Strict asepsis is naturally a paramount requirement. 
In general, the efficacy of RS is 75% to 80%, and RS can 
be performed in patients of any age. RS is performed to 
reduce the number and intensity of hemarthroses and the 
amount of cartilage damage caused by intra-articular 
blood in the joint over the medium and long term.31 
majOr OrthOpedic Surgery
The most common interventions performed in hemophilic 
adults are TKAs (Figure 3). The joint pain and func-
tional disability caused by severe hemophilic arthropathy 
impairment are so intense that most patients require total 
joint arthroplasty. Hip arthropathy may cause charac-
teristic pain in the groin as well as pain radiating to the 
ipsilateral knee.
As already mentioned, it is sometimes advisable to 
operate 2 or 3 joints simultaneously (2 knees, or hip and 
knee) to obtain proper functioning of the lower limbs. 
In some cases, it is preferable to operate the more pain-
ful joint first and the less painful joint 3 to 6 months 
later. Prostheses of other joints (hips, shoulders, elbows, 
ankles) are rarely mentioned in the world literature on 
hemophilia.
TKA is typically performed with limb ischemia by a 
straight longitudinal incision and a medial parapatellar 
route inside. In hemophilia cases, many surgeons use 
antibiotic-loaded bone cement.16,17,32 The indication for 
a hip prosthesis is intense groin pain, sometimes radiat-
ing to the ipsilateral knee, with associated functional 
disability.16,17,33
A local fibrin seal is not always needed to achieve 
hemostasis during surgery in patients with hemophilia. 
However, using a fibrin seal can be good adjunct thera-
py, mainly in cases in which the surgical field may bleed 
more than expected, such as in patients with inhibitors, 
but also in some orthopedic procedures, mainly surgical 
removal of pseudotumors.
diScuSSiOn
Orthopedic surgery for hemophilic patients with inhibi-
tors often is complex and poses risks for bleeding 
(when hematologic control fails) and infection (when 
human immunodeficiency virus causes severe immuno-
deficiency). However, current hematologic manage-
ment allows surgeons to control hemostasis in these 
cases. APCCs and rFVIIa have made major orthopedic 
surgery possible. Hemophilic patients with inhibitors 
can go into required orthopedic surgery with a high 
expectation of success. 
Over the next 5 years, hematologic management of 
hemophilic patients with inhibitors should improve as 
a result of common use of enhanced on-demand treat-
ment of acute joint bleeds in these patients and better 
control of hemostasis during the perioperative period of 
orthopedic procedures. In other words, the orthopedic 
status and quality of life of these patients are expected 
to improve.
Enhanced on-demand treatment of acute hemarthro-
sis is paramount in hemophilic patients with inhibitors. 
The aim of this treatment is to reduce the intensity of 
the chronic synovitis and cartilage damage caused by 
intra-articular blood in the joint over the medium and 
long term. 
For acute hemarthrosis in patients with inhibitors, 
hematologic management must be maintained until 
bleeding goes into full remission and the patients 
have recovered as much of their preoperative range 
of motion and muscular strength as possible. Such a 
regimen (enhanced on-demand treatment) can take up 
to 3 months. In this connection, ultrasonography is a 
reliable, economical, and easy-to-use method for diag-
nosing hemarthrosis and following up on its evolution.
When chronic hemophilic synovitis is being managed, 
RS should always be performed first (Figure 1). Should 
RS fail 3 times (6-month intervals), arthroscopic syno-
vectomy is indicated.
In hemophilia, muscular problems must not be under-
estimated, given the risk for developing compartment 
syndrome, which requires surgical decompression, and 
pseudotumors, which require surgical removal or percu-
taneous management.
A local fibrin seal is not always needed to achieve 
hemostasis during surgery in patients with hemophilia. 
However, using a fibrin seal can be good adjunct therapy, 
mainly in cases in which the surgical field may bleed more 
than expected, such as in patients with inhibitors, but also 
in some orthopedic procedures, mainly surgical removal 
of pseudotumors.
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